Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4802249

LENACAPAVIR SODIUM
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c([N-]S(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O.[Na+]

Basic Information

ChEMBL ID CHEMBL4802249
Name LENACAPAVIR SODIUM
Phase Approved
Structure Type MOL
InChI Key SSXPGMNGIORJAQ-PZNXWHLTSA-M
Therapeutic ✓ Yes
Parent Compound CHEMBL4594438
Active Moiety CHEMBL4594438

Known Names

GS-6207-02 GS-HIV Na GS-HIV SODIUM Lenacapavir sodium Sunlenca
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
5
Known Names
2
Indications
1
Mechanisms

Molecular Properties

968.3
MW (Da)
7.66
ALogP
10
HBA
2
HBD
157.9
PSA (Ų)
0.10
QED
2
Ro5 Violations
11
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 2022
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Oral Parenteral

Flags

First in Class
USAN Stem -vir
USAN Year 2021

Extended Properties

Molecular Formula C39H31ClF10N7NaO5S2
MW 990.28
Aromatic Rings 5
Heavy Atoms 64
NP-Likeness -0.78

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Structural capsid protein inhibitor INHIBITOR Structural capsid protein

Indications

HIV Infections HIV-1

Data from ChEMBL 36 via Core Engine